0000914475-13-000075.txt : 20130905 0000914475-13-000075.hdr.sgml : 20130905 20130905173148 ACCESSION NUMBER: 0000914475-13-000075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130904 FILED AS OF DATE: 20130905 DATE AS OF CHANGE: 20130905 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gano Kyle CENTRAL INDEX KEY: 0001567160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 131081218 MAIL ADDRESS: STREET 1: NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-09-04 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001567160 Gano Kyle NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Business Dev Officer Common Stock 2013-09-04 4 S 0 2400 15.61 D 22488 D Non-statutory Stock Option 10.90 2013-09-04 4 X 0 2400 10.90 A 2007-09-26 2013-09-26 Common Stock 2400 0 D Exercise of in-the-money or at-the-money derivative security The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Margaret E. Valeur- Jensen, By Power of Attorney 2013-09-05